PHOENIX, AZ – June 12, 2025 – nVector, Inc. a leader in innovative solutions for neurodegenerative disease research, proudly announces the launch of its proprietary TDP-43 Assay Diluent, a cutting-edge tool designed to enhance the detection and quantification of TDP-43 protein in biofluids for amyotrophic lateral sclerosis (ALS) research. This novel diluent, optimized for use in electrochemiluminescence immunoassays, promises to revolutionize how researchers’ study TDP-43 proteinopathy, a critical feature present in 97% of ALS cases. Detailed in the 2025 study, “Development of a Sensitive and Reliable Meso Scale Discovery-Based Electrochemiluminescence Immunoassay to Quantify TDP-43 in Human Biofluids”, nVector’s TDP-43 Assay
Read More
